Latest Articles and Analysis

Quarterly update on HCV treatment coverage across ADAPs, Medicaid, Veterans programs, and patient assistance options.

Analysis of Kanawha County HIV outbreak highlighting substance use, rural healthcare gaps, and pandemic impact.

Housing instability increases HIV/HCV acquisition by 55-65%; housing investments outpace health interventions.

COVID-19 vaccination priority for people with HIV and chronic liver disease amid immunological risks.

Merck-Gilead partnership on long-acting injectables Islatravir and Lenacapavir for HIV treatment.

Assesses pandemic's ongoing impact on HIV, HCV, and SUD surveillance and care with vaccine rollout.

COVID-19 vaccine development spurs reflection on 35-year HIV vaccine search and mRNA technology advances.

Arizona's restrictive Medicaid formulary limits single-tablet HIV regimens and HCV agents post-expansion.

NASTAD's hepatitis C navigation toolkit uses peer navigators and wraparound services for people who use drugs.

Family courts and child welfare systems miss opportunities to address health needs and social determinants.

Multi-state Hepatitis A and B outbreaks linked to homelessness highlight housing as public health priority.

FDA approves Cabenuva, first long-acting injectable HIV regimen offering monthly alternative to daily pills.

HHS releases integrated Viral Hepatitis National Strategic Plan calling for a syndemic approach with HIV and STI.

Quarterly Watch covering HCV treatment access across ADAPs and Medicaid, harm reduction programs, and COVID-19 impact on care.

COVID-19 caused a 50% drop in hospital HCV screening and 72% drop in primary care settings.

Narrowly divided Senate limits Biden's health policy agenda, making regulatory actions the primary reform path.

Final rule allowing drug importation from Canada poses safety risks from counterfeit medications.

Evaluates pandemic's impacts on HIV, HCV, and SUD services including testing disruptions and telehealth expansion.

CANN outlines advocacy priorities for the Biden era, from 340B reform and drug pricing to HIV criminalization and health equity.